Patents by Inventor Grégory Lambert

Grégory Lambert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250352589
    Abstract: The present invention relates to a composition comprising a probiotic composition comprising a Lactobacillus salivarius strain and a Lactobacillus gasseri strain. The invention further relates to the nutraceutical and therapeutical uses of such compositions in oxytocin-related neuropsychiatric disorders, in particular autism or anxiety related disorders selected from depression and eating disorders.
    Type: Application
    Filed: September 16, 2022
    Publication date: November 20, 2025
    Inventors: Serguei FETISSOV, Marion NICOL, Clémentine PICOLO, Grégory LAMBERT
  • Patent number: 11319352
    Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: May 3, 2022
    Assignees: TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
    Inventors: Serguei Fetissov, Grégory Lambert, Romain Legrand, Nicolas Lucas
  • Publication number: 20220000941
    Abstract: A pharmaceutical or nutraceutical composition, including a Hafnia alvei strain probiotic composition; the strain expressing the ClpB protein; in association with zinc bisglycinate and/or chrome picolinate. Additionally, oral dosage forms of the pharmaceutical or nutraceutical composition including the Hafnia alvei strain probiotic composition in association with zinc bisglycinate and/or chrome picolinate.
    Type: Application
    Filed: November 28, 2019
    Publication date: January 6, 2022
    Applicant: TARGEDYS
    Inventors: Clémentine PICOLO, Grégory LAMBERT
  • Publication number: 20210401020
    Abstract: A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10?4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.
    Type: Application
    Filed: November 28, 2019
    Publication date: December 30, 2021
    Applicants: TARGEDYS, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
    Inventors: Clémentine PICOLO, Grégory LAMBERT, Romain LEGRAND, Nicolas LUCAS
  • Publication number: 20210107952
    Abstract: Methods of treating inflammation, in particular obesity, inducing satiation, prolonging satiety, and stimulating weight loss in a subject in need thereof, including the administration of a Brassicaceae protein extract. The Brassicaceae protein extract may be administered in the form of a dietary supplement or a food composition, either of which may include at least one additional ingredient.
    Type: Application
    Filed: April 3, 2018
    Publication date: April 15, 2021
    Applicants: TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
    Inventors: Serguei FETISSOV, Grégory LAMBERT, Romain LEGRAND, Nicolas LUCAS
  • Publication number: 20200131495
    Abstract: Polypeptides and proteins that include a fragment of a ClpB protein and compositions therefrom. Methods of treatment and/or prevention of inflammation, in particular overweight and/or obesity-related diseases and disorders, with the polypeptides and proteins. Also, methods of inducing satiation, prolonging satiety, reducing meal size, reducing food intake, controlling weight gain and stimulating weight loss with the polypeptides and proteins.
    Type: Application
    Filed: April 3, 2018
    Publication date: April 30, 2020
    Applicants: TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
    Inventors: Serguei FETISSOV, Grégory LAMBERT, Romain LEGRAND, Nicolas LUCAS, Manon DOMINIQUE
  • Patent number: 8512687
    Abstract: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: August 20, 2013
    Assignee: Novagali Pharma SA
    Inventors: Grégory Lambert, Laura Rabinovich-Guilatt, Frédéric Lallemand, Jean-Sébastien Garrigue, Betty Philips
  • Patent number: 8273362
    Abstract: Cationic ophthalmic oil-in-water type emulsions, include colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent and at least one non ionic surfactant, the oily core including a prostaglandin selected from the group comprising in particular latanoprost, unoprostone isopropyl, travoprost, bimatoprost, tafluprost, 8-isoprostaglandinE2, or a mixture thereof, for treating ocular hypertension and/or glaucoma. These emulsions have the property to increase the chemical stability of prostaglandins.
    Type: Grant
    Filed: October 10, 2005
    Date of Patent: September 25, 2012
    Assignee: Novagali Pharma S.A.
    Inventors: Betty Philips, Séverine Bague, Laura Rabinovich-Guilatt, Grégory Lambert
  • Publication number: 20110201689
    Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.
    Type: Application
    Filed: April 28, 2011
    Publication date: August 18, 2011
    Applicant: NOVAGALI PHARMA SA
    Inventors: Laura Rabinovich-Guilatt, Grégory Lambert, Frédéric Lallemand, Betty Philips
  • Publication number: 20110021443
    Abstract: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.
    Type: Application
    Filed: July 29, 2010
    Publication date: January 27, 2011
    Applicant: NOVAGALI PHARMA SA
    Inventors: Grégory LAMBERT, Laura RABINOVICH-GUILATT, Frédéric LALLEMAND, Jean-Sébastien GARRIGUE, Betty PHILIPS